Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals Plc    HIK   GB00B0LCW083

Delayed Quote. Delayed  - 05/31 05:35:08 pm
2298 GBp   +3.28%
05/25 HIKMA PHARMACEU : Michael Raya, CEO of West-Ward Pharmaceuticals, Hi..
05/24 DIRECTOR DEALIN : Hikma Pharmaceuticals CFO Sells 20,000 Shares
05/20 HIKMA PHARMACEU : wins Mitigare / Colchicine patent infringement cas..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA Board

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/25/2016 | 03:54pm CEST

Release date- 24052016 - London- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that Michael Raya, Chief Executive Officer of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, will join the Board of Directors of the Generic Pharmaceutical Association (GPhA).

Michael Raya said:

'The GPhA's Board and professional staff are terrific stewards of the industry. I am honored to add my voice to GPhA's leadership on critical issues of medicine access and affordability.'

Chip Davis, President and CEO, GPhA, said:

'Michael Raya is a proven industry leader whose addition to our Board will accelerate our work with Congress, the FDA, stakeholders and others to ensure that generic drugs and biosimilars continue providing millions of Americans with safe, effective and more affordable alternatives to costly brand products.'

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: 'Injectables', 'Branded' and 'Generics', based principally in the United States, the Middle East and North Africa (MENA) and Europe. Hikma currently employs over 7,000 staff members worldwide.

About West-Ward Pharmaceuticals

West-Ward Pharmaceuticals, a wholly-owned subsidiary of Hikma Pharmaceuticals PLC, is a top ten generic pharmaceutical company in the US focused on providing a broad range of differentiated generic pharmaceutical products across a range of dosage forms. West-Ward has sites in New Jersey, Ohio and Tennessee.

For further information on US-centric news, visit www.West-Ward.com or contact:

Keri Butler

Email: kbutler@west-ward.com

Tel: 614.272.4774

About GPhA

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals fill 88 percent of the prescriptions dispensed in the U.S. but consume just 28 percent of the total drug spending. Additional information is available at gphaonline.org. Follow us on twitter: @gpha.

For further information and latest news updates, visit www.Hikma.com or contact:

Hana Darwazeh Ramadan

Email: Media@Hikma.com

Tel: +962 6 580 2900

(c) 2016 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on HIKMA PHARMACEUTICALS PLC
05/25 HIKMA PHARMACEUTICALS : Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's ..
05/24 DIRECTOR DEALINGS : Hikma Pharmaceuticals CFO Sells 20,000 Shares
05/20 HIKMA PHARMACEUTICALS : wins Mitigare / Colchicine patent infringement case
05/19 HIKMA PHARMACEUTICALS : Says US Court Dismisses Claims Made By Takeda
05/12 HIKMA PHARMACEUTICALS : 25.6% Potential Upside Indicated by Barclays Capital
05/12 TOP NEWS : Hikma Reiterates Guidance For 2016 On Good Start
05/10 HIKMA PHARMACEUTICALS : receives Drug Shortage Assistance Award from US FDA
05/05 HIKMA PHARMACEUTICALS : receives FDA approval for Fluphenazine Decanoate Injecti..
05/05 HIKMA PHARMACEUTICALS : receives FDA approval for Leucovorin Calcium Injection
04/12 HIKMA PHARMACEUTICALS : DIRECTOR DEALINGS: Hikma Non-Executive Director Buys Fir..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials